1.21
-0.01 (-0.82%)
| Penutupan Terdahulu | 1.22 |
| Jumlah Dagangan | 362,983 |
| Harga / Jualan (P/S) | 1.58 |
| Harga / Buku (P/B) | 1.49 |
| Julat 52 Minggu |
| Margin Keuntungan | -156.48% |
| Margin Operasi (TTM) | -247.80% |
| EPS Cair (TTM) | -1.28 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -36.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.71% |
| Nisbah Semasa (MRQ) | 2.56 |
| Aliran Tunai Operasi (OCF TTM) | -33.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.01 M |
| Pulangan Atas Aset (ROA TTM) | -37.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -107.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Spero Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.67 |
|
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 24.61% |
| % Dimiliki oleh Institusi | 23.25% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |